| Literature DB >> 30632965 |
Hugh Cameron McCall1, Fjola Dogg Helgadottir2,3,4, Ross G Menzies5, Heather D Hadjistavropoulos1, Frances S Chen6.
Abstract
BACKGROUND: Social anxiety is both harmful and prevalent. It also currently remains among the most undertreated major mental disorders, due, in part, to socially anxious individuals' concerns about the stigma and expense of seeking help. The privacy and affordability of computer-aided psychotherapy interventions may render them particularly helpful in addressing these concerns, and they are also highly scalable, but most tend to be only somewhat effective without therapist support. However, a recent evaluation of a new self-guided, 7-module internet-delivered cognitive behavioral therapy intervention called Overcome Social Anxiety found that it was highly effective.Entities:
Keywords: cognitive behavioral therapy; internet; mental health; psychotherapy; social anxiety
Mesh:
Year: 2019 PMID: 30632965 PMCID: PMC6329899 DOI: 10.2196/11566
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Flowchart of user progress.
User characteristics and questionnaire scores.
| Characteristic | Completers (n=102) | Noncompleters (n=267) | Total (N=369) | ||
| Female, n (%) | 39 (40.2) | 98 (38.4) | 137 (39.0) | ||
| Age, mean (SD)b | 35.47 (13.64) | 33.88 (11.93) | 34.31 (12.42) | ||
| Seen therapist for anxiety, n (%) | 45 (47.9) | 129 (52.0) | 174 (50.9) | ||
| Seen therapist for other reasons, n (%) | 43 (45.3) | 96 (38.9) | 139 (40.6) | ||
| Taken medication for anxiety, n (%) | 36 (37.5) | 120 (48.6) | 156 (45.5) | ||
| Pretreatment, mean (SD) | 25.91 (3.99) | 25.53 (5.05) | 25.63 (4.78) | ||
| Posttreatment, mean (SD) | 15.06 (8.32) | — | — | ||
| 13.61 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 1.76 | — | — | ||
| Pretreatment, mean (SD) | 14.07 (10.07) | 16.34 (11.28) | 15.72 (10.99) | ||
| Posttreatment, mean (SD) | 7.57 (8.60) | — | — | ||
| 7.42 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 0.70 | — | — | ||
| Pretreatment, mean (SD) | 9.93 (6.84) | 12.42 (8.212) | 11.73 (7.93) | ||
| Posttreatment, mean (SD) | 5.32 (5.64) | — | — | ||
| 8.24 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 0.74 | — | — | ||
| Pretreatment, mean (SD) | 16.28 (8.05) | 18.14 (9.40) | 17.63 (9.08) | ||
| Posttreatment, mean (SD) | 10.01 (7.63) | — | — | ||
| 9.57 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 0.80 | — | — | ||
| Pretreatment, mean (SD) | 79.72 (23.40) | 80.66 (23.68) | 80.40 (23.57) | ||
| Posttreatment, mean (SD) | 44.93 (24.17) | — | — | ||
| 16.47 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 1.46 | — | — | ||
| Pretreatment, mean (SD) | 51.37 (14.85) | 52.35 (15.59) | 52.08 (15.37) | ||
| Posttreatment, mean (SD) | 29.54 (15.97) | — | — | ||
| 15.40 (101) | — | — | |||
| <.001 | — | — | |||
| Cohen | 1.42 | — | — | ||
aSome users did not respond to certain questions. The 5 rows beneath this heading display responses from 97 completers and 255 noncompleters who reported their sex, 92 completers and 246 noncompleters who reported their age, 94 completers and 248 noncompleters who reported whether or not they had previously seen a therapist for anxiety, 95 completers and 247 noncompleters who reported whether or not they had previously seen a therapist for another reason, and 96 completers and 247 noncompleters who reported whether or not they had previously taken medication for anxiety. The percentages given represent percentages of respondents, not percentages of participants overall.
bAge was measured by year of birth, and our statistics on users’ ages represent their ages at the end of the calendar years during which they began the intervention.
cThis row displays the results of a within-subjects t test comparing completers’ pre- and posttreatment scores.
dDASS: Depression Anxiety Stress Scales.
Feedback from completers.
| Feedback theme | n (%) | |
| General praise (eg, | 26 (25.5) | |
| Specific symptom improvement (eg, | 18 (17.6) | |
| Content quality (eg, | 12 (11.8) | |
| Components (eg, | 9 (8.8) | |
| Presentation (eg, | 9 (8.8) | |
| Convenience or accessibility (eg, | 6 (5.9) | |
| Cost (eg, | 3 (2.9) | |
| Privacy (eg, | 3 (2.9) | |
| Ease of use (eg, | 2 (2.0) | |
| Components (eg, | 10 (9.8) | |
| Presentation (eg, | 7 (6.9) | |
| Content quality (eg, | 4 (3.9) | |
| Research considerations (eg, | 2 (2.0) | |
| Technical problems (eg, | 2 (2.0) | |
| Cost (eg, | 1 (1.0) | |
| Specific lack of symptom improvement (eg, | 1 (1.0) | |
| Length (eg, | 1 (1.0) | |